èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã X4 Pharmaceuticals, Inc. ã¯ãåžå°çŸæ£ã®æ²»çã®ããã®æ°ããæ²»çæ³ã®ç ç©¶ãéçºãããã³åååã«æ³šåããŠããŸããå瀟ã®äž»å補ååè£ã¯ãã±ã¢ã«ã€ã³åå®¹äœ CXCR4 ã®çµå£å°ååæ®æè¬ã§ãããããªããµãã©ã«ã§ããããã¯ãç£èŽ
ãäœã¬ã³ãã°ãããªã³è¡çãææçãããã³éªšé«ã«ããã·ã¹çåçŸ€ã®æ£è
ã®æ²»çãç®çãšãã第 III çžèšåºè©Šéšãéçå
倩æ§å¥œäžçæžå°çããã³ã¯ã«ãã³ã·ã¥ãã¬ãŒã ãã¯ãã°ãããªã³è¡çãæ²»çããããã®ç¬¬ Ib çžèšåºè©Šéšãããã³æçŽ°èè
现èçã®æ²»çãç®çãšãã第 IIa çžèšåºè©Šéšãé²è¡äžã§ããå瀟ã¯ãŸããå€åœ¢æ§è èœè
«ã®æ²»çãç®çãšãã X4P-002ãããã³æ
¢æ§åžå°çŸæ£ã«èŠããæ£è
ã®æ²»çãç®çãšãã X4P-003 ãéçºäžã§ãã X4 Pharmaceuticals, Inc. 㯠Abbisko Therapeutics Co., Ltd. ãšã©ã€ã»ã³ã¹å¥çŽãç· çµããè
«çåŠã®é©å¿çã«ãããŠãã§ãã¯ãã€ã³ãé»å®³å€ãŸãã¯ä»ã®è¬å€ãšäœµçšãããããªããµãã©ã«ã®éçºã補é ãåååãè¡ã£ãŠããŸããå瀟㯠2014 幎ã«èšç«ãããããµãã¥ãŒã»ããå·ãã¹ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã